Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others

·7 min read

Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio, ADC Therapeutics, Amgen, Morphosys and Xencor.

Los Angeles, USA, May 10, 2021 (GLOBE NEWSWIRE) -- Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others

Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio, ADC Therapeutics, Amgen, Morphosys and Xencor.

DelveInsight’s “Anti-CD19 Antibody Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Anti-CD19 Antibody pipeline landscapes. It comprises Anti-CD19 Antibody pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Anti-CD19 Antibody therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Anti-CD19 Antibody pipeline products.

Some of the key takeaways of the Anti-CD19 Antibody Pipeline Report

  • Notable companies such as TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others are developing potential drug candidates to boost the Anti-CD19 Antibody treatment scenario.

  • In April 2021, Incyte and MorphoSys announced the first patient had been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).

  • In March 2021, Amgen reported positive data from the Phase III study of BLINCYTO (blinatumomab) in paediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukaemia (B-ALL).

  • In February 2021, Viela Bio announced additional positive results with UPLIZNA (inebilizumab-cdon) in patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum.

  • In November 2020, Xencor, MorphoSys and Incyte announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), first-line DLBCL, and relapsed or refractory follicular lymphoma (FL).

  • In June 2020, inebilizumab received its first global approval in the USA for the Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment in adult patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG). The drug is also undergoing clinical evaluation for kidney transplant desensitisation, myasthenia gravis, and IgG4-related disease.

Get an overview of pipeline landscape @ Anti-CD19 Antibody Clinical Trials Analysis

Anti-CD19 Antibody, a cluster of differentiation 19 (CD19), is a cell surface molecule expressed on B- lineage cells and follicular dendritic cells. CD19 comprises two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signalling in conjunction with CD21 and CD81.
CD19 is expressed throughout B-cell development and plays a critical role in maintaining the balance between humoral, antigen-induced immune response and tolerance induction.

Anti-CD19 Antibody Emerging Drugs

  • Inebilizumab: Viela Bio

Inebilizumab is a humanised monoclonal antibody designed to target and deplete CD19-expressing B cells through antibody-dependent cell-mediated cytotoxicity.

Research and Development
Myasthenia Gravis
Phase III

NCT04524273: In August 2020, Viela Bio initiated a randomised, double-blind, multicenter, placebo-controlled Phase 3 study with an open-label period to assess the efficacy and safety of Inebilizumab in adults with Myasthenia Gravis. This study is a phase 3, randomised, double-blind, placebo-controlled study conducted at approximately 100 study sites. About 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. The study is estimated to get completed by December 2024 with 252 registered participants.

IgG4-Related Disease
Phase III
NCT04540497: In October 2020, Viela Bio initiated a Phase 3, randomised, double-blind, multicenter, and placebo-controlled study of Inebilizumab efficacy and safety in IgG4-Related Disease. This study focuses on defining the effectiveness and safety of Inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD). The study is estimated to get completed by June 2024 with 160 enrolled participants.

For further information, refer to the detailed report @ Anti-CD19 Antibody Pipeline Therapeutics

Scope of Anti-CD19 Antibody Pipeline Drug Insight

  • Coverage: Global

  • Major Players: 15+ Key Players

  • Prominent Players: TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and many others.

  • Key Drugs Profiles: 15+ Products

  • Phases:

  • Anti-CD19 Antibody Therapies Late-stage (Phase III)

  • Anti-CD19 Antibody Therapies Mid-stage (Phase II)

  • Anti-CD19 Antibody Therapies Early-stage (Phase I)

  • Anti-CD19 Antibody Pre-clinical stage and Discovery candidates

  • Discontinued and Inactive candidates

  • Mechanism of Action:

  • CD-19 Antagonist

  • Molecule Types:

  • Antibody

  • Route of Administration:

  • Intravenous

  • Parenteral

  • Product Types:

  • Monotherapy

  • Combination

  • Mono/Combination

Key Questions regarding Current Anti-CD19 Antibody Treatment Landscape and Emerging Therapies Answered in the Pipeline Report

  • What are the current options for Anti-CD19 Antibody treatment?

  • How many companies are developing therapies for the treatment of Anti-CD19 Antibody?

  • How many are Anti-CD19 Antibody emerging therapies in the early-stage, mid-stage, and late development stages to treat Anti-CD19 Antibody?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Anti-CD19 Antibody market?

  • Which are the dormant and discontinued products and the reasons for the same?

  • What is the unmet need for current therapies for the treatment of Anti-CD19 Antibody?

  • What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Anti-CD19 Antibody therapies?

  • What are the critical designations that have been granted for the emerging therapies for Anti-CD19 Antibody?

  • How many patents are granted and pending for the emerging therapies to treat Anti-CD19 Antibody?

Table of Contents

1

Anti-CD19 Antibody Report Introduction

2

Anti-CD19 Antibody Executive Summary

3

Anti-CD19 Antibody Overview

4

Anti-CD19 Antibody – DelveInsight’s Analytical Perspective In-depth Commercial Assessment

5

Anti-CD19 Antibody Pipeline Therapeutics

6

Anti-CD19 Antibody Late Stage Products (Phase III)

6.1

Inebilizumab : Viela Bio

7

Anti-CD19 Antibody Mid Stage Products (Phase II)

7.1

Coltuximab ravtansine : Sanofi

8

Anti-CD19 Antibody Early Stage Products (Phase I/II)

8.1

GNR-084: Generium Pharmaceutical

9

Anti-CD19 Antibody Early Stage Products (Phase I)

9.1

DI-B4: Merck KGaA

10

Anti-CD19 Antibody Therapeutic Assessment

11

Anti-CD19 Antibody Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Anti-CD19 Antibody Key Companies

14

Anti-CD19 Antibody Key Products

15

Anti-CD19 Antibody Unmet Needs

16

Anti-CD19 Antibody Market Drivers and Barriers

17

Anti-CD19 Antibody Future Perspectives and Conclusion

18

Anti-CD19 Antibody Analyst Views

19

Appendix

20

About DelveInsight

Get a customised pipeline report @ Anti-CD19 Antibody Drugs Pipeline Report

Related Reports

DelveInsight's Advanced Renal Cell Carcinoma (RCC) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight’s Global Kinase Inhibitor Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight's Alzheimer's disease Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of disease and understanding of historical and forecasted epidemiology.

DelveInsight's Anemia in CKD patients - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight's ATCL Market report 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market trends in 7MM.

Hidradenitis Suppurativa Market Research Report presents a detailed analysis of HS Epidemiology, Drug therapies, and pipeline for the study period from 2017-2030.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Portfolio Management Services to understand the competencies, leverage strengths to prioritise strategic goals and understand the market’s current needs.

CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com